Literature DB >> 11985788

Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread.

Hiroko Bando1, Gaku Matsumoto, Masaki Bando, Mariko Muta, Taeko Ogawa, Nobuaki Funata, Jun Nishihira, Morio Koike, Masakazu Toi.   

Abstract

Macrophage migration inhibitory factor (MIF) is known to exert pleiotropic functions including inhibition of macrophage migration, anchoring, and counteraction of the anti-inflammatory and immunosuppressive activity of glucocorticoids. Ninety-three primary breast cancer tissues and 64 sera of primary breast cancer patients were analyzed for the expression of MIF. The clinico-pathological significance of MIF expression was evaluated. It was found that MIF was frequently over-expressed in primary breast cancer tissues. RT-PCR and western blotting analysis confirmed that wild-type MIF is expressed, and immunohistochemical analysis showed that MIF expression was localized at tumor cells as well as stromal cells, including tumor-associated macrophages. Intratumoral MIF protein concentrations detected by enzyme-linked immunosorbent assay (ELISA) varied with a median value of 1821 ng/mg protein (range: 8 - 8126 ng/mg protein), and correlated inversely with nodal involvement (P = 0.039). No significant correlation was observed with other clinico-pathological factors including tumor size, menopausal status and hormone receptors. The circulating level of MIF protein ranged up to 105.7 ng/ml (median: 17.3 ng/ml), and it was also found to correlate inversely with the number of involved nodes (P = 0.02). A comparative study with other soluble inflammatory mediators showed that intratumoral levels of MIF were significantly associated with those of interleukin-1 beta, suggesting that interactions between tumor cells and tumor-associated macrophages play an important role in the up-regulation of MIF. The multifunctional inflammatory/immune mediator MIF was frequently expressed in primary breast cancer, and its expression level was inversely associated with nodal spread. Thus, MIF seems to play a role in tumor-stroma interactions of primary breast cancers, particularly those with a phenotype of node-negative or minimal nodal spread.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11985788      PMCID: PMC5927007          DOI: 10.1111/j.1349-7006.2002.tb01269.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  40 in total

Review 1.  The origin and function of tumor-associated macrophages.

Authors:  A Mantovani; B Bottazzi; F Colotta; S Sozzani; L Ruco
Journal:  Immunol Today       Date:  1992-07

2.  Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells.

Authors:  Y Yang; P Degranpré; A Kharfi; A Akoum
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

3.  Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria.

Authors:  T Calandra; L A Spiegel; C N Metz; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

4.  An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.

Authors:  M Bacher; C N Metz; T Calandra; K Mayer; J Chesney; M Lohoff; D Gemsa; T Donnelly; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

5.  Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes.

Authors:  M T del Vecchio; S A Tripodi; F Arcuri; L Pergola; L Hako; R Vatti; M Cintorino
Journal:  Prostate       Date:  2000-09-15       Impact factor: 4.104

6.  Mechanism of a reaction in vitro associated with delayed-type hypersensitivity.

Authors:  B R Bloom; B Bennett
Journal:  Science       Date:  1966-07-01       Impact factor: 47.728

7.  Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis.

Authors:  T Shimizu; R Abe; A Ohkawara; Y Mizue; J Nishihira
Journal:  Biochem Biophys Res Commun       Date:  1997-11-07       Impact factor: 3.575

8.  Identification of macrophage migration inhibitory factor (MIF) in human skin and its immmunohistochemical localization.

Authors:  T Shimizu; A Ohkawara; J Nishihira; W Sakamoto
Journal:  FEBS Lett       Date:  1996-03-04       Impact factor: 4.124

9.  MIF as a glucocorticoid-induced modulator of cytokine production.

Authors:  T Calandra; J Bernhagen; C N Metz; L A Spiegel; M Bacher; T Donnelly; A Cerami; R Bucala
Journal:  Nature       Date:  1995-09-07       Impact factor: 49.962

10.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.

Authors:  T Calandra; J Bernhagen; R A Mitchell; R Bucala
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more
  45 in total

1.  Clinicopathological significance of macrophage migration inhibitory factor and its relation with p53 in gastric cancer.

Authors:  Majid Nabizadeh Marvast; Hamid Reza Sima; Kamran Ghaffarzadehgan; Ali Taghizadeh Kermani; Nona Norouzi
Journal:  J Gastrointest Cancer       Date:  2011-03

2.  The cytokine midkine and its receptor RPTPζ regulate B cell survival in a pathway induced by CD74.

Authors:  Sivan Cohen; Or-yam Shoshana; Einat Zelman-Toister; Nitsan Maharshak; Inbal Binsky-Ehrenreich; Maya Gordin; Inbal Hazan-Halevy; Yair Herishanu; Lev Shvidel; Michal Haran; Lin Leng; Richard Bucala; Sheila Harroch; Idit Shachar
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

3.  Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas.

Authors:  Chia-Tung Shun; Jaw-Town Lin; Shih-Pei Huang; Min-Tsan Lin; Ming-Shiang Wu
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

4.  Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases.

Authors:  Leandro Marcelo Martinez; Valeria Beatriz Fernández Vallone; Vivian Labovsky; Hosoon Choi; Erica Leonor Hofer; Leonardo Feldman; Raúl Horacio Bordenave; Emilio Batagelj; Federico Dimase; Ana Rodriguez Villafañe; Norma Alejandra Chasseing
Journal:  Clin Exp Metastasis       Date:  2013-10-31       Impact factor: 5.150

5.  Association Between Genetic Polymorphism of the MIF Gene and Colorectal Cancer in Taiwan.

Authors:  Latha Ramireddy; William Tzu-Liang Chen; Ching-Tien Peng; Rouh-Mei Hu; Tao-Wei Ke; Hua-Che Chiang; Sheng-Chi Chang; Fuu-Jen Tsai; Wan-Yu Lo
Journal:  J Clin Lab Anal       Date:  2014-05-19       Impact factor: 2.352

6.  Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer.

Authors:  Long-Jun He; Dan Xie; Pin-Jin Hu; Yi-Ji Liao; Hai-Xia Deng; Hsiang-Fu Kung; Sen-Lin Zhu
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

Review 7.  Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation.

Authors:  Beatriz E Rendon; Sharon S Willer; Wayne Zundel; Robert A Mitchell
Journal:  Exp Mol Pathol       Date:  2009-01-07       Impact factor: 3.362

8.  The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer.

Authors:  Hakan Camlica; Derya Duranyildiz; Hilal Oguz; Ethem Nezih Oral; Vildan Yasasever
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

9.  Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis.

Authors:  X-X He; J Yang; Y-W Ding; W Liu; Q-Y Shen; H H-X Xia
Journal:  Gut       Date:  2006-02-17       Impact factor: 23.059

10.  Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer.

Authors:  Eva Verjans; Erik Noetzel; Nuran Bektas; Anke K Schütz; Hongqi Lue; Birgitt Lennartz; Arndt Hartmann; Edgar Dahl; Jürgen Bernhagen
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.